Summary
-
1.
Nicotine, an important pharmacological component of cigarette smoke, is known to have significant effects on central nervous system (CNS) dopaminergic function. Although acute doses of nicotine have been shown to facilitate dopamine release, recent data indicate that chronic nicotine treatment may actually decrease CNS dopamine turnover in the striatum.
-
2.
A number of epidemiological investigations have demonstrated that individuals who are or who have been smokers areless likely to develop idiopathic Parkinson's disease (a disorder involving a deficit in nigrostriatal dopaminergic neurotransmission). In addition, there is preliminary evidence that individuals with tardive dyskinesia (a hyperkinetic movement disorder observed in some cases of chronic neuroleptic treatment and thought by some to be associated with striatal dopamine receptor supersensitivity) aremore likely to be smokers.
-
3.
A unitary hypothesis is presented, proposing that smoking in early adult life may decrease CNS catecholamine turnover, thereby protecting against free radical formation from catecholamine oxidation that in turn damages striatal neurons. These individuals are thereby “protected” from the later development of Parkinson's disease. In this hypothetical scheme, individuals who are given neuroleptics and who also are smokers may develop a greater degree of dopamine receptor supersensitivity due to combined receptor blockade by neuroleptics and a decrease in CNS dopamine turnover caused by nicotine, resulting in an increased prevalence of tardive dyskinesia in this group.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arqueros, L., Naquira, D., and Zunino, E. (1978). Nicotine-induced release of catecholamines from rat hippocampus and striatum.Biochem. Pharmacol. 272667–2674.
Balfour, D. J. K. (1982). The effects of nicotine on brain neurotransmitter systems.Pharmacol. Ther. 16269–282.
Barochovsky, O., and Bradford, H. F. (1987). Modulation of dopamine release from neuron-enriched tissue cultures by cholinergic agents.J. Neurochem. 48798–803.
Baron, J. A. (1986). Cigarette smoking and Parkinson's disease.Neurology 361490–1496.
Benowitz, N. L. (1986). Clinical pharmacology of nicotine.Annu. Rev. Med. 37 21–32.
Bharucha, N. E., Stokes, L., Schoenberg, B. S., Ward, C., Ince, S., Nutt, J. G., Eldridge, R., Calne, D. B., Mantel, N., and Duvoisin, R. (1986). A case-control study of twin pairs discordant for Parkinson's disease: A search for environmental risk factors.Neurology 36284–288.
Binder, R. L., Kazamatsuri, H., Nishimura, T., and McNeil, D. E. (1987). Smoking and tardive dyskinesia.Biol. Psychiat. 22 1280–1282.
Calne, D. B., and Langston, J. W. (1983). Aetiology of Parkinson's disease.Lancet 21457–1459.
Clarke, P. B. S. (1987). Nicotine and smoking: A perspective from animal studies.Psychopharmacology 92135–143.
Clarke, P. B. S., and Pert, A. (1985). Autoradiographic evidence for nicotine receptors on nigrostriatal and mesolimbic dopaminergic neurons.Brain Res. 348355–358.
Clarke, P. B. S., Hommer, D. W., Pert, A., and Skirboll, L. R. (1985). Electrophysiological actions of nicotine on substantia nigra single units.Br. J. Pharmacol. 85 827–835.
Cohen, G. (1984). Oxy-radical toxicity in catecholamine neurons.Neurotoxicology 577–82.
Connelly, M. S., and Littleton, J. M. (1983). Lack of stereoselectivity in ability of nicotine to release dopamine from rat synaptosomal preparations.J. Neurochem. 411297–1302.
Doll, R., and Peto, R. (1976). Mortality in relation to smoking: 20 years' observations on male British doctors.Br. Med. J. 21525–1536.
Giorguieff-Chesselet, M. F., Kemel, M. L., Wandscheer, D., and Glowinski, J. (1979). Regulation of dopamine release by presynaptic nicotinic receptors in rat striatal slices: Effect of nicotine in a low concentration.Life Sci. 251257–1262.
Godwin-Austen, R. B., Lee, P. N., Marmot, M. G., and Stern, G. M. (1982). Smoking and Parkinson's disease.J. Neurol. Neurosurg. Psychiat. 45577–581.
Golbe, L. I., Cody, R. A., and Duvoisin, R. C. (1986). Smoking and Parkinson's disease: Search for a dose-response relationship.Arch. Neurol. 43774–778.
Goodman, F. R. (1974). Effects of nicotine on distribution and release of14C-norepinephrine and14C-dopamine in rat brain striatum and hypothalamus slices.Neuropharmacology 131025–1032.
Graham, D. G., Tiffany, S. M., Bell, W. R., and Gutknecht, W. F. (1978). Autoxidation versus covalent binding of quinones as the mechanism of toxicity of dopamine, 6-hydroxydopamine, and related compounds toward C1300 neuroblastoma cellsin vitro.Mol. Pharmacol. 14644–653.
Jann, M. W., Saklad, S. R., Ereshefsky, L., Richards, A. L., Harrington, C. A., and Davis, C. M. (1986). Effects of smoking on haloperidol and reduced haloperidol plasma concentrations and haloperidol clearance.Psychopharmacology 90468–470.
Jeste, D. V., and Wyatt, R. J. (1981). Dogma disputed: Is tardive dyskinesia due to postsynaptic dopamine receptor supersensitivty?J. Clin. Psychiat. 42455–457.
Jeste, D. V., and Wyatt, R. J. (1982).Understanding and Treating Tardive Dyskinesia, Guilford Press, New York.
Kahn, H. A. (1966). The Dorn study of smoking and mortality among U.S. veterans: Report on eight and one-half years of observation. InEpidemiological Approaches to the Study of Cancer and Other Chronic Diseases (W. Haenszel, Ed.), U.S. Department of Health, Education and Welfare, National Cancer Institute Monograph 19, pp. 1–27.
Kirch, D. G., Gerhardt, G. A., Shelton, R. C., Freedman, R., and Wyatt, R. J. (1987). Effect of chronic nicotine administration on monoamine and monoamine metabolite concentrations in rat brain.Clin. Neuropharmacol. 10376–383.
Langston, J. W. (1985). MPTP and Parkinson's disease.TINS 879–83.
Lichtensteiger, W., Hefti, F., Felix, D., Huwyler, T., Melamed, E., and Schlumpf, M. (1982). Stimulation of nigrostriatal dopamine neurones by nicotine.Neuropharmacology 21963–968.
Perry, T. L., Godin, D. V., and Hansen, S. (1982). Parkinson's disease: A disorder due to nigral glutathione deficiency?Neurosci. Lett. 33305–310.
Pomerleau, O. F., and Pomerleau, C. S. (1984). Neuroregulators and the reinforcement of smoking: Towards a biobehavioral explanation.Neurosci. Biobehav. Rev. 8503–513.
Rajput, A. H., Offord, K. P., Beard, C. M., and Kurland, L. T. (1987). A case-control study of smoking habits, dementia, and other illnesses in idiopathic Parkinson's disease.Neurology 37226–232.
Todes, C. J., and Lees, A. J. (1985). The pre-morbid personality of patients with Parkinson's disease.J. Neurol. Neurosurg. Psychiat. 4897–100.
Ward, C. D., Duvoisin, R. C., Ince, S. E., Nutt, J. D., Eldridge, R., and Calne, D. B. (1983). Parkinson's disease in 65 pairs of twins and in a set of quadruplets.Neurology 33815–824.
Yassa, R., Lal, S., Korpassy, A., and Ally, J. (1987). Nicotine exposure and tardive dyskinesia.Biol. Psychiat. 2267–72.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kirch, D.G., Alho, A.M. & Wyatt, R.J. Hypothesis: A nicotine-dopamine interaction linking smoking with Parkinson's disease and tardive dyskinesia. Cell Mol Neurobiol 8, 285–291 (1988). https://doi.org/10.1007/BF00711170
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00711170